Canagliflozin in dialysis patients
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether the drug canagliflozin (a type of diabetes medicine) is safe and works in people on dialysis. It may help improve fluid balance or blood sugar control in hemodialysis patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been on hemodialysis for more than 3 months.
- You must be 18 years of age or older.
- You must be willing to sign a consent form.
- You cannot have had a heart attack, stroke, heart failure, or a heart procedure in the last 3 months.
- You cannot have active cancer, peripheral artery disease, or severe claustrophobia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
This trial tests if canagliflozin, a diabetes medication, can help people with very advanced kidney disease or who recently started dialysis. It uses MRI scans to see how the drug affects the heart and kidneys.
This trial tests if canagliflozin, a diabetes medicine, helps remove extra fluid and reduce scarring in people on peritoneal dialysis (home-based dialysis). It may improve your dialysis results and protect your belly lining.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
Hear when a new Dialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.